Variable | All (n = 411) | Test cohort (n = 329) | Validation cohort (n = 82) | p value |
---|
Mean/% | SD | Mean/% | SD | Mean/% | SD |
---|
Age | 56.5 | 14.6 | 56.7 | 14.6 | 55.7 | 14.4 | 0.57 |
SJC28 | 6.1 | 5.4 | 6.3 | 5.4 | 5.4 | 5.3 | 0.14 |
TJC28 | 9.3 | 6.0 | 9.4 | 5.9 | 9.0 | 6.7 | 0.68 |
Duration | 11.7 | 7.0 | 11.8 | 7.0 | 11.1 | 6.8 | 0.37 |
CDAI | 25.9 | 12.8 | 26.2 | 12.5 | 24.5 | 14.1 | 0.32 |
CRP | 21.6 | 31.4 | 21.3 | 32.2 | 22.9 | 28.3 | 0.67 |
DAS28 | 4.6 | 1.3 | 4.6 | 1.3 | 4.5 | 1.4 | 0.42 |
Female | 62.8 | | 61.1 | | 69.5 | | 0.16 |
ACPA+ | 29.4 | | 28.6 | | 32.9 | | 0.44 |
RF+ | 29.4 | | 28.9 | | 31.7 | | 0.62 |
RA | 75.2 | | 76.9 | | 68.3 | | 0.11 |
Non-RA | 24.8 | | 23.1 | | 31.7 | | 1.00 |
SpoA | 2.9 | | 2.7 | | 3.6 | | |
PsoA | 3.6 | | 3 | | 6.1 | | |
PMR | 0.5 | | 0 | | 2.4 | | |
CTD | 1.9 | | 1.2 | | 4.9 | | |
uA | 15.9 | | 16.2 | | 14.7 | | |
- Baseline characteristics and diagnoses at 2 years follow-up of the total cohort, which was randomly split into a test cohort (80%) and a validation cohort (20%). SJC28 28 joint swollen joint count, TJC28 28 joint tender joint count, Duration symptom duration in weeks [wk], CDAI clinical disease activity index, CRP C-reactive protein, ACPA+ anti-citrullinated peptide antibody positive, RF+ IgM rheumatoid factor positive, RA rheumatoid arthritis, SpoA spondyloarthritis, PsoA psoriatic arthritis (not included in SpoA category), PMR polymyalgia rheumatica, CTD connective tissue disease, uA undifferentiated arthritis. p values indicate comparison between test and validation cohorts by T test, Wilcoxon’s test, or Fisher’s exact test, as indicated